Abstract:ABSTRACT Background We tested 400 NSCLC pts for ALK, EGFR and KRAS status and correlated clinical factors with ALK status and overall survival (OS). Methods ALK status was assessed with RACE-PCR, IHC and FISH; EGFR and KRAS status were assessed by direct DNA sequencing. OS was estimated by the Kaplan-Meier method. Results Consecutive, unselected cases from southern (n = 294) and northern (n = 106) China were tested; 31 (7.7%), 105 (26.2%) and 33 (8.2%) pts were ALK + , EGFR+ and KRAS + , respectively. ALK and EGFR aberrations were largely exclusive (P = 0.009); 2 cases were ALK + /EGFR+. ALK+ status was associated with female sex (P = 0.023), non/light-smoking (P = 0.001) and adenocarcinoma (P = 0.017), and was more prevalent in southern (9.2%; 27/294) than northern (3.8%; 4/106) pts. The ALK fusion partner was EML4 in all 31 cases; predominantly variants V1–3 (90.3%, 28/31). In 326 modeled pts, female sex (HR = 2.84; P = 0.022), wild type EGFR (HR = 15.87; P = 0.001), non/light-smoking (HR = 3.95; P = 0.021) and adenocarcinoma (HR = 4.12; P = 0.031) were associated with ALK+. In 187 cases evaluated by IHC and RACE-PCR, IHC sensitivity was 100% (19/19; [5 IHC + ; 10 IHC + +; 4 IHC + ++ ]) and specificity was 79.8% (134/168). All 19 ALK+ cases by RACE-PCR were also ALK+ by FISH. In the first 303 pts, there were no significant OS differences between ALK + , EGFR + , KRAS+ and triple-negative pts, between ALK+ and ALK– pts, or between ALK+ cases matched with non-TKI-treated controls balanced for disease stage, sex, histology and EGFR/KRAS status. In ALK+ pts, non/light-smoking status (P = 0.016) and prior surgery (P = 0.024) were associated with increased OS by log-rank test. In a Cox model, disease stage (P ≤ 0.001 for both stage I and II), and surgical treatment (P = 0.001) were prognostic for OS. Conclusion ALK fusion prevalence was 7.7% overall, and was higher in southern pts. ALK+ was associated with non/light-smoking, adenocarcinoma and female sex. ALK fusion variants were mostly V1–3, which may inform RT-PCR screening. IHC for ALK protein and FISH for ALK rearrangement may be useful for patient selection. ALK+ was not a favorable prognostic factor, although disease stage and smoking history may influence OS in ALK+ NSCLC. Disclosure C. Blanckmeister: Employment: Pfizer. Myself. Compensated. Stock ownership: Pfizer. Myself. J. Chen: Employment: Senior Medical Affairs Therapeutic Area Manager. Pfizer. Myself. Compensated. All other authors have declared no conflicts of interest.

PUB106 Different ALK/ROS1 Variants in Prognosis of Surgical NSCLC Patients

[Clinical Features of 54 Cases of Lung Adenocarcinomas with C-Ros Oncogene 1 Fusion].

ROS1 Fusions in Chinese Patients with Non-Small-cell Lung Cancer.

Screening of Nsclc Samples from Chinese Lung Cancer Patients for Activating Rearrangements of the Alk, Ret, and Ros1 Genes.

High feasibility of cytological specimens for detection of ROS1 fusion by reverse transcriptase PCR in Chinese patients with advanced non-small-cell lung cancer.

Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion

Retrospective Study of Clinicopathologic Factors Associated with Alk Rearrangement and Survival Outcome in Chinese Patients (PTS) with NSCLC

Detecting Alk, Ros1 and Ret Fusion Genes in Cell Block Samples

ALK and ROS1 Rearrangements, Coexistence and Treatment in Epidermal Growth Factor Receptor-Wild Type Lung Adenocarcinoma: a Multicenter Study of 732 Cases

The Prevalence and Clinical Characteristics of ALK and ROS1 Fusions in East Asian Patients with Non-Small Cell Lung Cancer

MA26.05 Comprehensive Analysis of Treatment Response and Progression Pattern in Chinese Patients with Different ALK Fusion-Variants

Clinicopathological Characteristics and Outcomes of ROS1-rearranged Patients with Lung Adenocarcinoma Without EGFR, KRAS Mutations and ALK Rearrangements.

Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer

Feasibility of Cytological Specimens for ALK Fusion Detection in Patients with Advanced NSCLC Using the Method of RT-PCR.

Association of EGFR Mutation or ALK Rearrangement with Expression of DNA Repair and Synthesis Genes in Never‐smoker Women with Pulmonary Adenocarcinoma

Advanced Lung Adenocarcinomas with ROS1-rearrangement Frequently Show Hepatoid Cell

Clinical difference on the variants and co-mutation in a Chinese cohort with ALK-positive advanced non-small cell lung cancer

High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma

P1.13-08 Distribution, Differences in Clinical Characteristics and Resistance Mechanism of ALK Variants in Chinese Lung Cancer Patients

Concurrent Classic Driver Oncogenes Mutation with ROS1 Rearrangement Predicts Superior Clinical Outcome in NSCLC Patients.

ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.